BR112012006172A2 - derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia - Google Patents

derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia

Info

Publication number
BR112012006172A2
BR112012006172A2 BR112012006172A BR112012006172A BR112012006172A2 BR 112012006172 A2 BR112012006172 A2 BR 112012006172A2 BR 112012006172 A BR112012006172 A BR 112012006172A BR 112012006172 A BR112012006172 A BR 112012006172A BR 112012006172 A2 BR112012006172 A2 BR 112012006172A2
Authority
BR
Brazil
Prior art keywords
hyperlipidemia
obesity
diabetes
treatment
oxindole derivatives
Prior art date
Application number
BR112012006172A
Other languages
English (en)
Inventor
Fajun Nan
Jia Li
Li Chen
Lichun Feng
Lifang Yu
Mei Zhang
Mengwei Huang
Tao Pang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012006172A2 publication Critical patent/BR112012006172A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia. um composto de fórmula (i) bem como o sal farmacêuticamente aceitável do mesmo, em que r~ 1~ a r~ 7~ têm o significado exposto na reivindicação 1, poder ser usado como um medicamento.
BR112012006172A 2009-09-21 2010-09-20 derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia BR112012006172A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2009/074060 WO2011032320A1 (en) 2009-09-21 2009-09-21 Novel alkene oxindole derivatives
PCT/EP2010/063770 WO2011033099A1 (en) 2009-09-21 2010-09-20 Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia

Publications (1)

Publication Number Publication Date
BR112012006172A2 true BR112012006172A2 (pt) 2016-05-31

Family

ID=43414813

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006172A BR112012006172A2 (pt) 2009-09-21 2010-09-20 derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia

Country Status (10)

Country Link
US (3) US20110071195A1 (pt)
EP (1) EP2480530A1 (pt)
JP (1) JP2013505281A (pt)
KR (1) KR20120068876A (pt)
AU (1) AU2010297252A1 (pt)
BR (1) BR112012006172A2 (pt)
CA (1) CA2772674A1 (pt)
IN (1) IN2012DN00765A (pt)
MX (1) MX2012002477A (pt)
WO (2) WO2011032320A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
WO2013119774A1 (en) * 2012-02-10 2013-08-15 Virginia Commonwealth University 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2769974A1 (en) * 2013-02-21 2014-08-27 Debiopharm S.A. Novel AMPK activator
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014202528A1 (en) * 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
EP2886541A1 (en) * 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
CN106619616A (zh) * 2015-11-04 2017-05-10 中国科学院上海药物研究所 3-烯基吲哚酮类衍生物在制备治疗miri药物中的用途及其药物组合物
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201266T3 (es) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited Inhibidores del espesamiento de la capa intima.
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1935883A4 (en) * 2005-09-14 2010-07-21 Dainippon Sumitomo Pharma Co OXINDOL DERIVATIVES AS A MEANS FOR CONTROLLING FOOD RECEPTION
AU2007294686B2 (en) * 2006-09-15 2013-10-31 Equinox Sciences, Llc Kinase inhibitor compounds
US8129390B2 (en) * 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
EA019309B1 (ru) * 2008-02-04 2014-02-28 Меркьюри Терапьютикс, Инк. Модуляторы ampk (амф-активируемой протеинкиназы)
CA2741672A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Also Published As

Publication number Publication date
US20140288127A1 (en) 2014-09-25
EP2480530A1 (en) 2012-08-01
US8778973B2 (en) 2014-07-15
WO2011032320A1 (en) 2011-03-24
US20130131114A1 (en) 2013-05-23
AU2010297252A1 (en) 2012-02-02
MX2012002477A (es) 2012-03-26
JP2013505281A (ja) 2013-02-14
WO2011033099A1 (en) 2011-03-24
IN2012DN00765A (pt) 2015-06-26
KR20120068876A (ko) 2012-06-27
CA2772674A1 (en) 2011-03-24
US20110071195A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
BR112014003198A2 (pt) compostos para o tratamento e profilaxia de doença por vírus sincicial respiratório
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
BR112012026338A2 (pt) novos derivados de 3,3-dimetil tetrahidroquinolina
PH12015501678A1 (en) Inhibitors of influenza viruses replication
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112012023021A2 (pt) compostos de indazol e seus usos
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
GT201200164A (es) "nuevos compuestos de espiropiperidina"
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
BR112015007647A2 (pt) derivados de quetamina
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112014012983A2 (pt) derivados de pirrol
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.